TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

Inclusion Criteria: * Signed informed consent form. * Diagnosis of stage IV non-small cell lung cancer. * Male or female patients aged 18 years or older. * Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye. * Patients who have received up to 3 cycles of atezolizumab at the screening visit. Exclusion Criteria: * Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication. * Known or suspected hypersensitivity to atezolizumab. * Pregnant or breastfeeding women.